Jia Luo, MD(@Jia_Luo) 's Twitter Profileg
Jia Luo, MD

@Jia_Luo

@DanaFarber @harvardmed thoracic medical oncologist and cancer researcher // Prev MSKCC Fellow, OHSU IM & Chief Res, Stanford Med, and UW-Madison #GlobalCook

ID:308338117

linkhttps://www.dropbox.com/s/diiz6mc4sr4ek0b/JL%20disclosures.docx?dl=0 calendar_today31-05-2011 07:15:38

869 Tweets

931 Followers

397 Following

Ask the Question(@ATQ_TheMovie) 's Twitter Profile Photo

Welcome to 'Ask the Question!' Let's work together to help tell the incredible story of Dr. Ben Barres.

tinyurl.com/p8u7sxux

account_circle
Yi Zhe Ang(@yizhe_ang) 's Twitter Profile Photo

Happy to share my new interactive article / explorable on K-Means Clustering, which has also been accepted to VISxAI at IEEE VIS!

k-means-explorable.vercel.app

Built with and .

account_circle
Jia Luo, MD(@Jia_Luo) 's Twitter Profile Photo

Inspiring 2022 with Team Lung Cancer walking for our patients on a lovely Sunday in Boston

Amazing leadership by captain Elaine Kelley: organizing 50 walkers & walking the entire 26.2 mi!

Inspiring #JimmyFundWalk 2022 with Team Lung Cancer walking for our patients on a lovely Sunday in Boston Amazing leadership by captain Elaine Kelley: organizing 50 walkers & walking the entire 26.2 mi! #lcsm
account_circle
Sohrab Shah(@SohrabShah) 's Twitter Profile Photo

Thank you Nature Cancer for reviewing our study nature.com/articles/s4301… demonstrating multimodal data integration increases capacity to predict ICB response in non-small cell lung cancer. Terrific work led by Rami Vanguri Jennifer Sauter, MD Jia Luo, MD and many others. 1/8

account_circle
Stephen V Liu, MD(@StephenVLiu) 's Twitter Profile Photo

results can be confusing & difficult to understand for patients & their families. Check out the new LUNGevity Foundation “Reading a Biomarker Testing Report” created in partnership with ACCC Association for Molecular Pathology IASLC & APSHO for help.

tinyurl.com/2nxx87rh

#Biomarker results can be confusing & difficult to understand for patients & their families. Check out the new @LUNGevity “Reading a Biomarker Testing Report” created in partnership with @ACCCBuzz @AMPath @IASLC & @APSHOorg for help. #LCSM tinyurl.com/2nxx87rh
account_circle
Laurie Glimcher MD(@LGlimcherMD) 's Twitter Profile Photo

A recent report based on a symposium sponsored by Dana-Farber calls for new measures to address NUT carcinoma, including new clinical trials for patients with this rare and devastating cancer. blog.dana-farber.org/insight/2022/0…

account_circle
Jarushka Naidoo(@DrJNaidoo) 's Twitter Profile Photo

Which pts with SD from ICIs are ‘responders’(have similar outcomes to those w PR/CR)?

- systemic rev 59 ICI trials comparing SD pts to those w PR/CR v PD by BOR &PFS
- pts w PFS >6mo+no tumor growth, similar to those w PR

Annals of Oncology Jia Luo, MD
sciencedirect.com/science/articl…

account_circle
Jia Luo, MD(@Jia_Luo) 's Twitter Profile Photo

Thank you to all faculty - esp Bruce, Keith, Ross Levine, Michael Postow, Bernardo, Ryan, Tatiana Prowell, MD - for sharing their time & wisdom with us!

Awesome colleagues and timely/ high-yield early career workshop spanning the spectrum of translational research

account_circle
Jia Luo, MD(@Jia_Luo) 's Twitter Profile Photo

A stellar academic med Gurpreet Dhaliwal must-read for July --- 'The Greatest Generation' on professionalism, fostering a culture of respect, and the growth mindset

jamanetwork.com/journals/jama/… ht Dr AngelaLam

A stellar academic med @Gurpreet2015 must-read for July --- 'The Greatest Generation' on professionalism, fostering a culture of respect, and the growth mindset jamanetwork.com/journals/jama/… ht Dr AngelaLam
account_circle
Annals of Oncology(@Annals_Oncology) 's Twitter Profile Photo

Multiple driver alterations are drug targets in advanced NSCLC 🫁. With the emergence of allele-specific KRAS inhibitors, @jia_luo and coll. investigate clinicopathologic, genomic, & immunophenotypic characteristics of NSCLC with KRAS G12D mutations

annalsofoncology.org/article/S0923-…

Multiple driver alterations are drug targets in advanced NSCLC 🫁. With the emergence of allele-specific KRAS inhibitors, @jia_luo and coll. investigate clinicopathologic, genomic, & immunophenotypic characteristics of NSCLC with KRAS G12D mutations #LCSM annalsofoncology.org/article/S0923-…
account_circle